SEED Therapeutics
Biotechnology ResearchNew York, United States11-50 Employees
SEED Therapeutics is a biotechnology company focused on developing molecular glue degraders that target disease-causing proteins previously regarded as undruggable. By enabling the targeted destruction of these proteins, the company aims to broaden treatment options for severe diseases with limited existing therapies. It builds a growing pipeline through collaborations with leading academic experts and with seasoned drug development and commercialization specialists, advancing candidates toward clinical testing and eventual commercialization. Headquartered in New York, New York, SEED Therapeutics situates itself in the biotechnology research sector, exploring protein degradation as a path to novel therapeutics. Its work targets diseases with unmet medical needs, aiming to provide options for healthcare professionals and patients where current treatments are scarce. The company has publicly highlighted progress on its RBM39-targeting program, ST-01156, which is in a first-in-human Phase 1 study, and has participated in major oncology conferences such as ASCO 2026 to share updates.
1-888-653-2347 
support@leadiq.com 
